• Founded: 2019
  • Location: New York, NY
  • Employee range: 50 - 200
  • Clinical stage: Clin2
  • Therapy area: liver metastasis, pancreatic cancer
  • Drug types: ONC
  • Lead product: Odetiglucan
  • Product link: https://hibercell.com/pipeline/
  • Funding: $67.4M B May 2021; $61M A Feb 2019



job board

Short description:

Tumor dormancy detection and treatments

Drug notes:

HC-5404 Clin1 advanced solid tumors; HC-7366 Clin1 solid tumors

Long description:

HiberCell is advancing novel therapeutics that target adaptive stress pathways. Treatment resistance, cancer relapse and metastasis are unfortunate outcomes for cancer patients. By targeting the induction of adaptive stress, a common feature of these outcomes, HiberCell is pioneering a new cancer treatment paradigm. With this strategy, HiberCel has developed a differentiated pipeline of therapy candidates: this includes HC-5404, a differentiated, orally bioavailable investigational small molecule inhibitor of PERK, a kinase of the unfolded protein response. As preclinical models show PERK activation in response to various cancer therapies, HiberCell is looking to test the therapy for advanced solid tumors.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com